Core Viewpoint - The article discusses the turnaround of Hanyu Pharmaceutical, which is expected to achieve a net profit of 40 to 50 million yuan in 2025, marking its first return to profitability in three years, driven by the growth of GLP-1 raw materials and CRDMO business [5][6]. Financial Performance - Hanyu Pharmaceutical's revenue is projected to reach 950 to 980 million yuan in 2025, a significant increase from 590 million yuan in 2024, indicating a stepwise improvement rather than a one-time recovery [6]. - The company has signed a 180 million yuan sales contract for GLP-1 raw materials, which is expected to significantly enhance its profit structure [7][8]. Market Dynamics - The GLP-1 raw material market is becoming increasingly competitive, with major players like CordenPharma investing over 900 million euros in expanding their production capacity in the U.S. and Europe [8]. - Domestic competitors such as Nuotai Bio and Shengnuo Bio are also ramping up production, leading to a shift in customer selection criteria from availability to stability, cost-effectiveness, and reliability [8]. Future Outlook - While the increase in GLP-1 raw material production has pushed Hanyu Pharmaceutical into profitability, the sustainability of orders and pricing will be tested as competition intensifies [9]. - The recent performance signals improvements in cash flow and order fulfillment, but the company must maintain its position in a rapidly crowded market [9].